The second major category is life sciences. In 2011 we made some changes for our sales delivery organization to align this business around certain momentum of verticals. Our life sciences team is really the first one of these that’s getting its sea lengths (ph) and is clearly benefiting from this new org structure.Our proven dedicated expertise in this domain and concentrating that among a few delivery centers and with a core sales team and a separate general manager winning new business and growing accounts in the contract research sector and also with medical device clients and we also recently secured a new win at a very large pharma company. So our investments and focus on last year in the life sciences area are paying off and I think we’ll find another vertical in 2012 and do the same thing to set us up for 2013.
Lionbridge's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts